A recent study indicates that patients who stop using new weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who end conventional lifestyle regimens.
Findings released in a major medical journal points out that while overweight people frequently drop substantial amounts of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Individuals using these treatments must be aware of the potential of quick rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment mass within about a year and a half.
Weighing Approaches
The analysis, which looked at 37 of trials involving thousands of patients, contrasted the results of the injectable medications with older methods.
Scientists point out that people who shed pounds through dieting typically see a slower weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Doctors propose the mode of action of the jabs is key to understanding the amplified regain.
These medications copy a natural hormone called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels several times higher than the body's typical production could lead to the system to produce less of its own natural hormone, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication results in appetite is no longer kept in check, making overeating a significant risk."
A Chronic Condition?
The NHS suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, given the significant potential of relapse, the therapy should be considered ongoing.
This perspective is supported by drug manufacturers, who say that the results "emphasize the long-term character of excess weight," comparing it to managing conditions like hypertension.
User Testimonies
People who have come off the medication report a sudden resurgence of appetite.
"It was like a trigger activating and you become starving," described a patient.
This difficulty is compounded if patients have not established lasting dietary or behavioural changes during therapy.
Growing Use
Figures show that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Use is greater among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
In conclusion, clinicians stress that while the jabs are potent tools for shedding pounds, they are not a magic fix and long-term success relies on integrated behavioural management.
